An interventional study of SYNOLIS VA 40/80 in Osteo Arthritis Knee, sponsored by Aptissen SA. Completed at 3 sites in Poland. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-26.
Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.
Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 64th largest by enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2021, is one of 28 with no phase, and was the 44th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 60–100
Novo Nordisk A/S · Sites in Poland, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 16 · Phase 4 10
First in 2007; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 115 across the 72 interventional studies, 131 across the 6 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 78 have an industry lead sponsor. The 10 most frequent:
Aptissen SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Aptissen SA has 4 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Knee with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449442Poznan University of Medical SciencesSII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty | 2026-11-30 |
| NCT07813078University of RzeszowAnti-Gravity Treadmill Gait Training for Knee Osteoarthritis | 2026-12-31 |
| NCT07677215Poznan University of Medical SciencesACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Osteoarthritis, Knee with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicentre, independent assessment study on SYNOLIS VA 40/80 over a period of 24 weeks
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
This study's enrollment of 51 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →Aptissen SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with knee osteoarthritis. The diagnosis is based on the following American College of Rheumatology (ACR) classification:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg), intra-articular injection
Device: SYNOLIS VA 40/80
Three 2mL injections of SYNOLIS VA 40/80, one week apart
Difference in total Western Ontario and McMaster Universities Arthritis index (WOMAC) score total between D168 and inclusion visit.
The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)
Time frame: 168 days
Change in pain measurements, assessed using the Western Ontario and McMaster Universities Arthritis (WOMAC) pain severity index, as compared to D0
The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)
Time frame: up to 168 days
Change in the Western Ontario and McMaster Universities Arthritis (WOMAC) functional severity index, as compared to D0
The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)
Time frame: up to 168 days
Change in the Western Ontario and McMaster Universities Arthritis (WOMAC) stiffness severity index, as compared to D0
The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)
Time frame: up to 168 days
Pain at walking on a 100 mm VAS
Time frame: up to 168 days
Percentage of subjects using analgesics
New NSAID / analgesics drugs usage
Time frame: up to 168 days
Measurement of relief satisfaction by the patient
7-point Likert scale (1 point very unsatisfied to 7 points for very satisfied)
Time frame: 168 days
Measurement of therapeutic efficacy by the investigator (assessor)
7-point Likert scale (1 point very unsatisfied to 7 points for very satisfied)
Time frame: 168 days
Safety and tolerability of SYNOLIS VA 40/80 assessed with adverse events monitoring throughout the study duration
Time frame: 168 days
Ran from Dec 2021 to primary completion in Jan 2023, 12 months.
Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 12 months is below that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aptissen SA